Biogen says ALS drug shows clinical benefit in new data analysis Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

A combined 12-month analysis of data from a late-stage trial and an open-extension study of tofersen, showing more positive results than the Phase III trial alone in patients with the rare type of ALS, was published in the New England Journal of Medicine., A combined 12-month analysis of data from a late-stage trial and an open-extension study of tofersen, showing more positive results than the Phase III trial alone in patients with the rare type of ALS, was published in the New England Journal of Medicine., , Read More